PHARMACODYNAMICS AND PHARMACOKINETICS 5 á-Reductase Isozyme Sensitivity to Finasteride : Species Differences

@inproceedings{Finn2006PHARMACODYNAMICSAP,
  title={PHARMACODYNAMICS AND PHARMACOKINETICS 5 {\'a}-Reductase Isozyme Sensitivity to Finasteride : Species Differences},
  author={Deborah Ann Finn and Amy S. Beadles-Bohling and Ethan H. Beckley and Matthew M. Ford and Katherine R. Gililland and Rebecca E. Gorin-Meyer and Kristine M. Wiren},
  year={2006}
}
Finasteride is the first 5á-reductase inhibitor that received clinical approval for the treatment of human benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern hair loss). These clinical applications are based on the ability of finasteride to inhibit the Type II isoform of the 5á-reductase enzyme, which is the predominant form in human prostate and hair follicles, and the concomitant reduction of testosterone to dihydrotestosterone (DHT). In addition to catalyzing the rate… CONTINUE READING